ES2192810T3 - Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis. - Google Patents
Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis.Info
- Publication number
- ES2192810T3 ES2192810T3 ES99106438T ES99106438T ES2192810T3 ES 2192810 T3 ES2192810 T3 ES 2192810T3 ES 99106438 T ES99106438 T ES 99106438T ES 99106438 T ES99106438 T ES 99106438T ES 2192810 T3 ES2192810 T3 ES 2192810T3
- Authority
- ES
- Spain
- Prior art keywords
- thermogenesis
- monoxidine
- employment
- medicinal
- stimulating activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000035924 thermogenesis Effects 0.000 title abstract 4
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960003938 moxonidine Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE DESCRIBE LA UTILIZACION DE MOXONIDINA Y SUS SALES DE ADICION DE ACIDO FISIOLOGICAMENTE ACEPTABLES PARA LA PRODUCCION DE PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO Y/O PREVENCION DE ALTERACIONES DE LA TERMOGENESIS, Y PARA ESTIMULAR LA TERMOGENESIS EN PERSONAS CON TRANSFORMACION DE ENERGIA ANORMALMENTE BAJA Y/O PERSONAS CON LA TERMOGENESIS DISMINUIDA DURANTE O AL FINAL DE UNA DIETA DE ADELGAZAMIENTO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19815411A DE19815411A1 (de) | 1998-04-06 | 1998-04-06 | Thermogenese stimulierend wirksame Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2192810T3 true ES2192810T3 (es) | 2003-10-16 |
Family
ID=7863781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99106438T Expired - Lifetime ES2192810T3 (es) | 1998-04-06 | 1999-03-29 | Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6069147A (es) |
| EP (1) | EP0951907B1 (es) |
| JP (1) | JPH11322607A (es) |
| CA (1) | CA2268213C (es) |
| DE (2) | DE19815411A1 (es) |
| ES (1) | ES2192810T3 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2849992B1 (fr) * | 2003-01-17 | 2007-03-16 | Inst Phytoceutic | Composition pour une administration par voie orale contenant des capsaicinoides |
| AU2007222069A1 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
| US20080140450A1 (en) * | 2006-11-28 | 2008-06-12 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with norfluoxetine |
| WO2009017755A2 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3904795C2 (de) * | 1989-02-17 | 2000-10-12 | Lilly Pharma Produktion Gmbh & | Pharmazeutisches Präparat und dessen Verwendung |
| US5977121A (en) * | 1995-02-28 | 1999-11-02 | Eli Lilly And Company | Use of moxonidine for the treatment of atherosclerosis |
| KR20000016406A (ko) * | 1996-06-06 | 2000-03-25 | 피터 지. 스트링거 | 울혈성 심장 마비 치료용 제제 및 방법_ |
-
1998
- 1998-04-06 DE DE19815411A patent/DE19815411A1/de not_active Withdrawn
-
1999
- 1999-03-29 DE DE59904415T patent/DE59904415D1/de not_active Expired - Fee Related
- 1999-03-29 ES ES99106438T patent/ES2192810T3/es not_active Expired - Lifetime
- 1999-03-29 EP EP99106438A patent/EP0951907B1/de not_active Expired - Lifetime
- 1999-04-01 CA CA002268213A patent/CA2268213C/en not_active Expired - Fee Related
- 1999-04-05 JP JP11098110A patent/JPH11322607A/ja not_active Withdrawn
- 1999-04-06 US US09/286,301 patent/US6069147A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2268213A1 (en) | 1999-10-06 |
| US6069147A (en) | 2000-05-30 |
| DE19815411A1 (de) | 1999-10-07 |
| DE59904415D1 (de) | 2003-04-10 |
| CA2268213C (en) | 2008-01-29 |
| EP0951907B1 (de) | 2003-03-05 |
| EP0951907A1 (de) | 1999-10-27 |
| JPH11322607A (ja) | 1999-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE173148T1 (de) | Kombinationspräparat zur förderung des haarwachstums und ggf. des haut- und nagelwachstums sowie zur verhinderung bzw. zur beseitigung von haarausfall | |
| ES2191329T3 (es) | Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares. | |
| CY1107143T1 (el) | Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου | |
| PT751778E (pt) | Utilizacao de agua com teor reduzido de deuterio para a producao de preparacoes higienicas e cosmeticas | |
| ES2157005T3 (es) | Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina. | |
| ES2192810T3 (es) | Empleo de monoxidina como medicamento de actividad estimulante de la termogenesis. | |
| DE122009000073I1 (de) | Arzneimittel zur behandlung von viralen haut- und tumorerkrankungen | |
| TW200501934A (en) | Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set | |
| DK1343472T3 (da) | Thixotropisk næsespray | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
| ATE330600T1 (de) | Kombinationspräparat zur krebstherapie | |
| PT1585513E (pt) | Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia | |
| HUP0402624A2 (hu) | Vírusgátlás n-dokozanollal | |
| EE200200549A (et) | Jagatud doosi teraapia veresooni kahjustava aktiivsusega | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| RU94000695A (ru) | Средство с противоаллергическим действием | |
| Wantke et al. | Topical podophyllotoxin in psoriasis vulgaris | |
| Maeng et al. | Pediatric onychomycosis treated with oral antifungal drugs | |
| SE9904863D0 (sv) | New use | |
| Strydom | In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire | |
| FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
| DE60322871D1 (de) | Thaltende zubereitungen | |
| RU97115801A (ru) | Способ лечения стенозирующих ларинготрахеитов у детей | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación |